Terms: = Ovarian cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP
6191 results:
1. Using Portuguese BRCA pathogenic variation as a model to study the impact of human admixture on human health.
Andaluz S; Zhao B; Sinha S; Lagniton PNP; Costa DA; Ding X; Brito M; Wang SM
BMC Genomics; 2024 Apr; 25(1):416. PubMed ID: 38671360
[TBL] [Abstract] [Full Text] [Related]
2. Germline mutations in brca1 and BRCA2 among Brazilian women with ovarian cancer treated in the Public Health System.
de Oliveira Ferreira C; Carneiro VCG; Araujo Mariz C
BMC Cancer; 2024 Apr; 24(1):499. PubMed ID: 38641594
[TBL] [Abstract] [Full Text] [Related]
3. Uptake of Risk-Reducing Measures, Cascade Testing, and Related Challenges Among Carriers of Breast cancer-Associated Germline Pathogenic Variants in Mexico.
Mesa-Chavez F; Chavarri-Guerra Y; Aguilar-Y-Mendez D; Becerril-Gaitan A; Vaca-Cartagena BF; Carrillo-Bedoya A; Santiesteban-González S; Aranda-Gutierrez A; Rodríguez-Faure A; Obregon-Leal D; Quintero-Beuló G; Rodriguez-Olivares JL; Miaja M; Weitzel JN; Villarreal-Garza C
JCO Glob Oncol; 2024 Apr; 10():e2300417. PubMed ID: 38635940
[TBL] [Abstract] [Full Text] [Related]
4. A Study on the Retrospective Reinterpretation of brca1 and BRCA2 Variants.
Kim JJ; Kim DJ; Nam EJ; Song KE; Ham JY; Kim YK; Lee NY
Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623660
[TBL] [Abstract] [Full Text] [Related]
5. Functional analysis and validation of oncodrive gene AP3S1 in ovarian cancer through filtering of mutation data from whole-exome sequencing.
Kong D; Wu Y; Liu Q; Huang C; Wang T; Huang Z; Gao Y; Li Y; Guo H
Eur J Med Res; 2024 Apr; 29(1):231. PubMed ID: 38609993
[TBL] [Abstract] [Full Text] [Related]
6. Olaparib Addition to Maintenance Bevacizumab Therapy in ovarian Carcinoma With BRCA-Like Genomic Aberrations.
Schouten PC; Schmidt S; Becker K; Thiele H; Nürnberg P; Richters L; Ernst C; Treilleux I; Medioni J; Heitz F; Pisano C; Garcia Y; Petru E; Hietanen S; Colombo N; Vergote I; Nagao S; Linn SC; Pujade-Lauraine E; Ray-Coquard I; Harter P; Hahnen E; Schmutzler RK
JAMA Netw Open; 2024 Apr; 7(4):e245552. PubMed ID: 38592722
[TBL] [Abstract] [Full Text] [Related]
7. Evaluating homologous recombination activity in tissues to predict the risk of hereditary breast and ovarian cancer and olaparib sensitivity.
Motonari T; Yoshino Y; Haruta M; Endo S; Sasaki S; Miyashita M; Tada H; Watanabe G; Kaneko T; Ishida T; Chiba N
Sci Rep; 2024 Apr; 14(1):7519. PubMed ID: 38589490
[TBL] [Abstract] [Full Text] [Related]
8. Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer.
Martincuks A; Zhang C; Austria T; Li YJ; Huang R; Lugo Santiago N; Kohut A; Zhao Q; Borrero RM; Shen B; Cristea M; Wang EW; Song M; Rodriguez-Rodriguez L; Yu H
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580335
[TBL] [Abstract] [Full Text] [Related]
9. Olaparib not cost-effective as maintenance therapy for platinum-sensitive, brca1/2 germline-mutated metastatic pancreatic cancer.
Mehra T; Lupatsch JE; Kössler T; Dedes K; Siebenhüner AR; von Moos R; Wicki A; Schwenkglenks ME
PLoS One; 2024; 19(4):e0301271. PubMed ID: 38573891
[TBL] [Abstract] [Full Text] [Related]
10. Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: experience from a clinical diagnostic center from greater Shanghai area.
Wu Z; Zhang Q; Jin Y; Zhang X; Chen Y; Yang C; Tang X; Jiang H; Wang X; Zhou X; Yu F; Wang B; Guan M
BMC Cancer; 2024 Apr; 24(1):411. PubMed ID: 38566028
[TBL] [Abstract] [Full Text] [Related]
11. Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade.
Nie H; Saini P; Miyamoto T; Liao L; Zielinski RJ; Liu H; Zhou W; Wang C; Murphy B; Towers M; Yang T; Qi Y; Kannan T; Kossenkov A; Tateno H; Claiborne DT; Zhang N; Abdel-Mohsen M; Zhang R
Nat Commun; 2024 Apr; 15(1):2853. PubMed ID: 38565883
[TBL] [Abstract] [Full Text] [Related]
12. Constitutional
Al-Moghrabi N; Al-Showimi M; Alqahtani A; Almalik O; Alhusaini H; Almalki G; Saad A; Alsunayi E
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542081
[TBL] [Abstract] [Full Text] [Related]
13. Frizzled class receptor 5 contributes to ovarian cancer chemoresistance through aldehyde dehydrogenase 1A1.
Xia Y; Wang S; Sun Y; Wang W; Chang S; Zhang Z; Zhao C
Cell Commun Signal; 2024 Mar; 22(1):194. PubMed ID: 38539211
[TBL] [Abstract] [Full Text] [Related]
14. Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of Prostate cancer.
Kalampokis N; Zabaftis C; Spinos T; Karavitakis M; Leotsakos I; Katafigiotis I; van der Poel H; Grivas N; Mitropoulos D
Curr Oncol; 2024 Feb; 31(3):1162-1169. PubMed ID: 38534919
[TBL] [Abstract] [Full Text] [Related]
15. High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency-Associated Genomic Instability in ovarian cancer.
Pfarr N; von Schwarzenberg K; Zocholl D; Merkelbach-Bruse S; Siemanowski J; Mayr EM; Herold S; Kleo K; Heukamp LC; Willing EM; Menzel M; Lehmann U; Bartels S; Chakraborty S; Baretton G; Demes MC; Döring C; Kazdal D; Budczies J; Rad R; Wild P; Christinat Y; McKee T; Schirmacher P; Horst D; Büttner R; Stenzinger A; Sehouli J; Vollbrecht C; Hummel M; Braicu EI; Weichert W;
JCO Precis Oncol; 2024 Mar; 8():e2300348. PubMed ID: 38513168
[TBL] [Abstract] [Full Text] [Related]
16. Characteristics of germline DNA damage response gene mutations in ovarian cancer in Southwest China.
Fu K; Li Q; Wang J; Zhang M; Yan X; Li K; Song L; Zhong L; Ma Y; Chen J; Zeng J; Wang D; Shao D; Zhu S; Yin R
Sci Rep; 2024 Mar; 14(1):6702. PubMed ID: 38509102
[TBL] [Abstract] [Full Text] [Related]
17. Systematic review of the molecular basis of hereditary breast and ovarian cancer syndrome in Brazil: the current scenario.
de Freitas Ribeiro AA; Junior NMC; Dos Santos LL
Eur J Med Res; 2024 Mar; 29(1):187. PubMed ID: 38504328
[TBL] [Abstract] [Full Text] [Related]
18. Oncological outcomes of intraperitoneal chemotherapy in advanced ovarian cancer: BRCA mutation role.
Padilla-Iserte P; Iváñez M; Muruzabal JC; Navarro R; Díaz-Feijoo B; Iacoponi S; García-Pineda V; Díaz C; Utrilla-Layna J; Gil-Moreno A; Serra A; Gilabert-Estellés J; Martínez Canto C; Tejerizo Á; Lago V; Cárdenas-Rebollo JM; Domingo S;
Eur J Surg Oncol; 2024 Apr; 50(4):108263. PubMed ID: 38492526
[TBL] [Abstract] [Full Text] [Related]
19. The analysis of preoperative or intraoperative factors in predicting the escalation of surgical pathological staging of patients with clinical stage I endometrioid carcinoma: A retrospective clinical study.
Li N; Chen Q; Li B
Medicine (Baltimore); 2024 Mar; 103(11):e37465. PubMed ID: 38489719
[TBL] [Abstract] [Full Text] [Related]
20. Different Patterns of Platinum Resistance in ovarian cancer Cells with Homologous Recombination Proficient and Deficient Background.
Chiappa M; Guffanti F; Grasselli C; Panini N; Corbelli A; Fiordaliso F; Damia G
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474294
[TBL] [Abstract] [Full Text] [Related]
[Next]
